RxDoctor Payments Data

Justin Goh, MD

Cardiovascular Disease · Henderson, NVNPI 1124554506

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.0%), food and beverage and grants — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 46.7% of the total. Reporting peaked in 2022 at $12,185 and has fallen 98.8% since, to $149 in 2025.

$17,248in general payments, 2019–2025

Across 212 payments — averaging $81.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Biotronik Inc.$5K
  • Boston Scientific$2K
  • Shockwave Medical, Inc$586
  • Amgen$584
  • Cardiovascular Systems Inc.$538
  • plus $1K from 8 others

What the payments were for

  • Grants$1,3008%
  • Travel & lodging$8,27448%
  • Food & beverage$7,67444%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,248 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$131,730
Medicare patients
513
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$269,330
Repatha SureclickEvolocumab106$73,928
EntrestoSacubitril/Valsartan49$62,838
JardianceEmpagliflozin19$16,224
XareltoRivaroxaban14$13,684
Rosuvastatin Calcium564$5,592
Atorvastatin Calcium283$2,472
Metoprolol Succinate216$2,243
Carvedilol147$1,636
Lisinopril187$1,338
Dofetilide12$1,333
Midodrine Hcl15$1,248
Amlodipine Besylate188$999
Toprol XlMetoprolol Succinate12$687
Potassium Chloride17$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$269,330208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →